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Data generated from cancer nanotechnology research are so diverse and large in volume that it is difﬁcult
to share and efﬁciently use them without informatics tools. In particular, ontologies that provide a uni-
fying knowledge framework for annotating the data are required to facilitate the semantic integration,
knowledge-based searching, unambiguous interpretation, mining and inferencing of the data using infor-
matics methods. In this paper, we discuss the design and development of NanoParticle Ontology (NPO),
which is developed within the framework of the Basic Formal Ontology (BFO), and implemented in the
Ontology Web Language (OWL) using well-deﬁned ontology design principles. The NPO was developed
to represent knowledge underlying the preparation, chemical composition, and characterization of
nanomaterials involved in cancer research. Public releases of the NPO are available through BioPortal
website, maintained by the National Center for Biomedical Ontology. Mechanisms for editorial and gov-
ernance processes are being developed for the maintenance, review, and growth of the NPO.
 2010 Elsevier Inc. All rights reserved.1. Introduction
Large and diverse types of data are being generated from
experiments in cancer nanotechnology research – an intrinsically
interdisciplinary ﬁeld of research devoted to the development
and application of nanotechnology-based methods in the treat-
ment, diagnosis, and detection of cancer. To efﬁciently use these
data, the cancer research community requires informatics meth-
ods that will help researchers to search, access, and analyze
nanomedicine data, and thereby facilitate the realization of nano-
technology applications in personalized treatment methods. In
particular, ontologies, which consist of a common vocabulary
and logical (information) structure are necessary components of
informatics because they provide the knowledge framework for
scientiﬁc discourse, and for the annotation, semantic integration,
knowledge-based searching, mining, inferencing and unambigu-
ous interpretation of data [1]. In this work, we develop an
ontology that represents the knowledge domain of cancer
nanotechnology.ll rights reserved.
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ker).1.1. Ontologies and their uses
An ontology is a formal, explicit representation of knowledge
belonging to a subject area: the knowledge is encoded and repre-
sented as multiple hierarchies of terms (or classes) that are de-
scribed using attributes (e.g., preferred name, deﬁnition,
synonyms, etc.), related to each other using associative relations
(e.g., part_of, has_part, etc.), and may be formalized using logical
axioms in a machine-interpretable language (e.g., Ontology Web
Language (OWL)) [2–6]. Ontologies are used in informatics-sup-
ported collaborative research and databases in different ways.
For example (1) ontologies provide a common terminology that
can be shared and re-used among researchers; (2) ontologies are
formally represented in a machine-readable language (e.g., OWL)
which can be meaningfully interpreted by both subject domain ex-
perts as well as computers; (3) ontologies facilitate semantic shar-
ing and integration of data stored in disparate resources by
providing the logical and semantic relationships between different
parts of information contained in data; (4) ontologies provide the
logical structure for performing knowledge-based searches along
with informatics tools and software in order to speed up the access
to, retrieval of, and analysis of data for enabling knowledge
discovery.
In addition to ontologies, there are controlled vocabularies
(CVs) that serve as terminology sources. A controlled vocabulary
(CV) provides a list of terms (organized in a hierarchy), textual
60 D.G. Thomas et al. / Journal of Biomedical Informatics 44 (2011) 59–74descriptions of their meaning, and lexical terms corresponding to
each entry [7]. Formally, vocabularies for informatics applications
are developed and made available in the form of CVs and/or ontol-
ogies. Compared to ontologies, however, CVs are limited in their
scope for informatics applications because they lack the expres-
siveness of ontologies in representing knowledge (an application
of CVs is in indexing resources, such as records in a database).
1.2. Ontologies in biomedical research
In biomedical research, ontologies are used to represent the
knowledge of a speciﬁc domain of interest in machine-processible
form and to integrate experimental data that is annotated with
terms from these ontologies. Biological and chemical ontologies
have played signiﬁcant roles in describing various characteristics
of genes and gene products (e.g., Gene Ontology or GO [8]), and
small molecular entities (e.g., Chemical Entities of Biological Inter-
est or ChEBI [9]). For example, the Gene Ontology (GO) serves as a
controlled vocabulary for describing gene and gene product attri-
butes in any organism [8]. Annotation of genes using GO terms
has provided ways to classify microarray experiments, thereby
enhancing the analysis, querying, and mining of microarray gene
expression data based on statistical methods [10]. Signiﬁcant effort
is being made to develop tools and methods to enable interopera-
bility among different biomedical ontologies for integrative analy-
sis of data from diverse experimental data sets in the biomedical
knowledge domain [11]. In this article, we will discuss the devel-
opment of an ontology for representing knowledge underlying
the diverse data arising from cancer nanotechnology research.
1.3. Importance of nanotechnology in cancer research
Nanotechnology involves the application of scientiﬁc knowl-
edge from a variety of disciplines in science and engineering to
understand, manipulate, and control the properties of matter at
nanoscale (1–100 nm) size dimensions [12]. Nanotechnology holds
tremendous potential for overcoming many of the problems that
conventional methods face in the treatment, diagnosis and detec-
tion of cancer [13]. In particular, nanoparticles (nanoscale-sized
particles) have been developed and investigated for cancer diag-
nostics and therapeutics; these materials are hereafter referred
to as NP-CDTs. Pre-clinical studies have shown that these NP-CDTs
offer many advantages over small-molecule approaches. For exam-
ple, NP-CDTs can ameliorate the problems of poor in vivo biodistri-
bution and adverse side effects associated with small-molecule
agents (e.g., drugs, image contrast agents, etc.). These problems
arise due to lack of speciﬁcity of the agents in targeting cancer cells
and are due to a range of effects such as: rapid uptake by the retic-
uloendothelial system (RES); clearance by the macrophages in MPS
(Mononuclear Phagocyte System) organs, if the intended target
cells are not located in the MPS organs; and the presence of barri-
ers (e.g., blood–brain barrier (BBB)) [14]. Cancer cells share many
features with normal cells, and therefore, agents lacking the de-
sired target speciﬁcity will also target healthy normal cells and
damage them, thereby, causing adverse side effects in the body.
In drug delivery, poor biodistribution of the drug can result in
low drug concentration levels at the tumor site. These low concen-
tration levels, in conjunction with dose-limiting toxic side effects,
reduce the drug’s overall therapeutic efﬁcacy. NP-CDTs can in-
crease the circulation times and efﬁcacy of therapeutic and diag-
nostic agents [13–16]. Generally, circulation times increase if the
agent of interest is attached to a small, hydrophilic nanoparticle
[17]. While small sizes reduce the likelihood of uptake by the
RES, hydrophilicity increases the overall solubility of the diagnos-
tic/therapeutic agent. In addition, functionalized nanoparticles tar-
get speciﬁc receptors that are over-expressed on surfaces of cancercells, and this in turn facilitates the uptake of drug-loaded nano-
particles via endocytic pathways [13–16]. In the year 2005, the
FDA (Food and Drug Administration) approved a paclitaxel-loaded
albumin nanoparticle formulation for the treatment of metastatic
breast cancer [18] – a positive advance for the therapeutic use of
NP-CDTs. Additionally, several other NP-CDTs are being evaluated
in clinical trials [19].
1.4. Informatics for advancing cancer nanotechnology research
Informatics methods are considered to be necessary tools for
the advancement of cancer nanotechnology research [20]. A cur-
sory evaluation of the literature reveals that NP-CDTs are diverse
in nature and have a wide range of applications [21,22]. This diver-
sity is related to combinatorially large numbers of mechanisms by
which the chemical composition of nanoparticles can be modiﬁed.
Furthermore, small changes in the chemical composition can cause
drastic changes in the physicochemical and functional/biological
properties of NP-CDTs, further increasing the volume and diversity
of nanomedicine datasets [23]. In fact, pre-clinical evaluation of
every new NP-CDT formulation requires experimental character-
izations to be done, and this in turn adds more volume and diver-
sity to the nanomedicine datasets. As the variety of nanoparticles
adapted for use as NP-CDTs has increased, the nanomedicine re-
search community has experienced signiﬁcant growth in NP-CDT
data. While the volume of NP-CDT data may be smaller than the
volume of genomic data, the complexity, richness, and direct ther-
apeutic or diagnostic relevance of NP-CDT data leads to a combina-
torial complexity that far exceeds genomic data. We propose that
the richness of this data can be tapped to develop customized
point-of-care treatment regimens based on NP-CDTs. Realization
of this objective will require an integrative approach for culling
data and drawing inferences that inform future de novo designs.
A particularly relevant example is the ‘‘rescue” of drug candidates
that have failed clinical trials. Often, failure is attributed to non-
speciﬁc delivery and toxic side effects. With increased data sharing
and integration, it should be possible to develop trials to ‘‘rescue”
failed drugs by loading them onto or encapsulating them into tar-
geted nanoparticles. It is expected that rational design of ‘‘rescue
strategies” will need predictions obtained from data-driven models
that have been tested and validated. It is desirable then to proceed
rationally with reformulations of therapeutic or diagnostic agents
using NP-CDTs. Informatics approaches are likely to be valuable
for such reformulation efforts, especially if one has access to an
integrated resource that yields rich information regarding both
the physicochemical and functional properties of NP-CDTs, as well
as tumor physiological properties.
1.5. Ontologies in cancer nanotechnology informatics
Ontologies will play an important role in the emerging ﬁeld of
cancer nanotechnology informatics. Recent efforts have focused
on the development of databases for storing cancer nanotechnol-
ogy data, with the goal of catalyzing discovery by bringing together
the key knowledge in nanotechnology into coalesced resources.
One such resource is the caNanoLab project [24], which has been
developed to store, search, and share data generated from a variety
of characterization studies for nanomaterials (e.g., NP-CDTs) used
in cancer nanotechnology research. However, to maximize utility,
databases must be complemented by a common vocabulary (or
‘‘terminology”) that can facilitate data sharing and integration of
nanotechnology databases with each other and with other can-
cer-related databases. A few terminologies for nanotechnology
are available in controlled vocabularies like the NCI (National Can-
cer Institute) Thesaurus [25] and through the efforts of caNanoLab,
ASTM (http://www.astm.org), ANSI (http://www.ansi.org/), the
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and the present work. However, with the exception of the current
work, most of these nanomedicine vocabulary efforts are at early
stages of development. In developing nanomedicine vocabularies,
one can also re-use other existing vocabulary sources to obtain
terms related to cancer biology (cancer cell lines, tumor types, ani-
mal models, genes, gene products, post-translational modiﬁca-
tions, and signaling pathways) and cancer medicine. Relevant
vocabularies for such terms include GO [8], ChEBI [9], NCI Thesau-
rus (NCIT) [25], Medical Subject Headings (MeSH) [26], SNO-
MED_CT (http://www.ihtsdo.org/our-standards/snomed-ct/), etc.
However, ontologies and controlled vocabularies focused speciﬁ-
cally on cancer nanotechnology have not been developed. In partic-
ular, ontologies – with their rich machine-interpretable logical
structure – are needed to facilitate communication between cancer
nanotechnology researchers from different scientiﬁc ﬁelds, to en-
sure semantic interoperability between applications and dat-
abases, and to provide the foundation for new analytical tools in
nanomedicine research. In addition to using the ontology to pro-
vide terms and deﬁnitions to help annotate data, we require ontol-
ogies to represent knowledge that is speciﬁc to the cancer
nanotechnology domain such that they can be used for semantic
integration of different parts of data, knowledge-based searching
and for drawing inferences, based on the logical classiﬁcation of
terms and relations between terms provided by the ontology. Con-
sider the following scenario as an example: a chemist has synthe-
sized a dextran-coated nanoparticle, but wants to make a rough
prediction about its in vitro and in vivo properties. So, s/he plans
to compare it with nanoparticles that have characterization data
available in a database such as caNanoLab. To make the best pre-
dictions, the researcher must identify that nanoparticle which
most closely correlates with the dextran-coated nanoparticle. For
this, the researcher must know what descriptors to choose from
for comparing the nanoparticles, and also know the optimal
descriptors needed to help determine the type of nanoparticle that
highly correlates with the dextran-coated nanoparticle. These
descriptors can be provided by the ontology. At the simplest level,
if the descriptor is type of coating material, then by classifying
nanoparticles based on this type of coating material will help iden-
tify the highly correlated classes of nanoparticles that are either
the sibling classes or child classes of dextran-coated nanoparticles.
In this way, the researcher only needs to look at nanoparticle data
annotated with the ontology classes, and to compare results of the
different nanoparticles identiﬁed from the classiﬁcation in the
ontology. Better predictive models such as Structure–Activity Rela-
tionship (SAR) models can be developed using data annotated and
integrated by an optimized set of ontology-based descriptors for
every case in question.
To address the need for ontologies in cancer nanotechnology
informatics, we have developed an ontology called the
NanoParticle Ontology (NPO). The NPO has been designed to rep-
resent knowledge underlying the preparation, chemical composi-
tion, physicochemical and functional/biological characterization
of nanomaterials (e.g., NP-CDTs), which are formulated and
tested for applications in cancer diagnostics and therapeutics.
The remainder of this manuscript details the development of
the NPO.2. Method
2.1. Initial collection of terms
We started the construction of NPO by creating an initial list of
terms pertaining to a general description of NP-CDTs in the litera-
ture. In the scientiﬁc literature, one ﬁnds that nanoparticles haveinherently very complex types of descriptions and therefore, re-
quire a wide range of classes that are deﬁned and logically related
in the NPO. The following examples illustrate the complexity with
which NP-CDTs are described in literature, and a few instances of
the types of classes and relationships that are needed for describ-
ing nanoparticles:
1. Entrapped gold dendrimers: These are nanoparticle formula-
tions that consist of gold nanoparticles entrapped in the core of
poly(amidoamine) dendrimers. In these formulations, some of
the amine surface groups of the dendrimer are covalently linked
to folic acid, which acts as a targeting agent for targeting folate
receptors that are over-expressed on the surfaces of certain types
of cancer cells (e.g., human epithelial carcinoma cells). To reduce
the toxicity of gold-dendrimer nanoparticles some amine groups
on the dendrimer surface are covalently linked to acetic anhydride.
Fluorescein isothiocyanate (FITC) is also covalently linked to a frac-
tion of the amine groups to enable ﬂuorescence imaging of the
nanoparticles [27]. This example illustrates the different physi-
cal ways in which nanoparticles can be functionalized with
other compounds and ligands for targeting and imaging.
2. Polymer micelles: Examples of these formulations include
anticancer drugs such as adriamycin (doxorubicin) conjugated to
polymer micelles through a pH-sensitive linker such as hydrazone.
When these nanoparticles are exposed to the acidic pH, the linkage
is destabilized, which consequently triggers the release of the
drugs in therapeutic applications [28]. This example illustrates
how nanoparticles can be functionalized using molecules with
speciﬁc roles for certain applications, based on a priori knowl-
edge of molecular properties (e.g., sensitivity of hydrazone to
acidic pH range) and physiological/tumor properties (e.g., pres-
ence of acidic pH in solid tumor).
3. An iron oxide nanoparticle formulation designed for imaging:
This example describes a crosslinked dextran-coated iron oxide
(superparamagnetic magnetic resonance contrast agent) nanopar-
ticle with a very complex composition [23,29]. The primary amine
groups of dextran are linked to N-succinimidyl 3-(2-pyridyldi-
thio)propionate (SPDP), a heterobifunctional amine- and sulfhy-
dryl-reactive crosslinker. The SPDP itself is linked to the C-
terminal cysteine residue of peptide (Arg)4-(Gly)-(Cys). Finally,
the N-terminal Arg residue of the peptide is linked to a ﬂuorescent
dye, a N-hydroxylsuccinimidyl (NHS) ester of Cys5.5. This example
illustrates the extremely complicated formulation of somemul-
tifunctional nanoparticle platforms.
Based on examples like the aforementioned ones, NP-CDTs can
be generally described in the following way: In general, a nanopar-
ticle formulation consists of chemical components that can be enu-
merated as (1) nanoparticles, (2) active chemical constituents,
which are part of the chemical makeup of the nanoparticle, and
(3) active chemical components which functionalize the nanopar-
ticle. There can be one or more types of nanoparticle in a nanopar-
ticle formulation, depending upon the nanoparticle structure,
function or chemical composition. All of the chemical components
can be described by theirmolecular structure, biochemical role, or
function. Besides enumerating and describing the chemical com-
ponents, one needs to describe the types of chemical linkages
(e.g., amide linkage, disulﬁde linkage, encapsulation, etc.) that exist
between them, and thereby provide an overall qualitative descrip-
tion of the chemical composition in a nanoparticle formulation.
Other descriptions include: physical locations of chemical compo-
nents in a nanoparticle (e.g., core, surface, etc.); shape of the nano-
particle (e.g., spherical, cylindrical, etc.); physical state of the
formulation (e.g., emulsion, hydrogel, etc.); physical, chemical or
functional properties of the active chemical components/constitu-
ents (e.g., organic, hydrophilic, magnetic, etc.); intended functions
and applications of chemical components for cancer treatment,
diagnosis and therapy; underlying mechanisms guiding the design
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etc.), and; type of stimulus that may be required for activating
nanoparticles (e.g., magnetic ﬁeld, ultrasound, pH change, etc.)
and the nanoparticle’s response to the stimulus (e.g., drug release
from nanoparticle in response to magnetic ﬁeld stimulus, heat gen-
eration from nanoparticle in response to stimulus of infrared light,
etc.).
We generated the initial list of terms from the literature. For
each type of information (listed in the previous paragraph), we
identiﬁed the header terms and relationships associating them.
This initial collection of terms and relationships provided the basis
for structuring the information content of NP-CDTs from the liter-
ature, based on which we collected more terms and organized
them in a taxonomic ‘‘is a” hierarchy. We adapted this initial hier-
archy to systematically and formally construct the NPO, using the
well-deﬁned design principles and best practices in ontology
development described below.
2.2. Design principles for the NPO
In this section, we discuss the design principles that were fol-
lowed in the development of the NPO. We selected the Basic For-
mal Ontology (BFO – version 1.1) as the upper-level ontology for
developing a structured classiﬁcation of NPO terms. BFO is a formal
ontology based on tested principles for biomedical ontologies [30].
There are several advantages to using the BFO framework for con-
structing the NPO: (1) the BFO provides a formal structure for clas-
siﬁcation of domain terms, (2) the BFO offers a set of well-deﬁned
principles known for best ontology practices in the biomedical are-
na, (3) the BFO helps make the NPO interoperable with other ontol-
ogies that have the formal structure of BFO, and (4) the BFO will
make the information represented in the ontology remain clear,
rigorous and unambiguous as it is expanded through collaborative
development. For a comprehensive account of the BFO, the reader
is directed to the BFO manual [30]. Only relevant BFO terms are
currently used in the NPO; however, other top-level BFO terms
may be added if needed.
We selected OWL-DL as the language for encoding the NPO be-
cause (1) OWL has formal semantics and additional vocabularies
which facilitate machine interoperability, (2) OWL is designed for
use in applications that process and present information to hu-
mans, and (3) due to the availability of the Protégé-OWL [31]
ontology editing software, which is intuitively designed for editing
OWL ﬁles and it greatly facilitates collaborative ontology develop-
ment by both ontologists and domain experts.
In the interest of completeness, the main design principles used
in developing the NPO are listed below. These design precepts are
based on BFO and Open Biomedical Ontologies (OBO) Foundry prin-
ciples (http://www.obofoundry.org/crit.shtml) aswell as our review
of other OWL-encoded ontologies and controlled vocabularies:
1. Principle of unbiased representation: Following BFO design
principles, any term in the ontology should represent an entity
as known in reality and not represent it from the biased view of
an individual.
2. Principle of asserted single ‘‘is a” inheritance: Again following
BFO principles, each term should have no more than one parent
term in the asserted OWL hierarchy. This principle offers the
advantages of making the ontology easily extensible and interoper-
able with other ontologies that have a formal structure. This
single-parent structure also helps to build the ontology in a mod-
ular fashion whereby different parts of the ontology can be worked
on independently [32].
3. Principle of inferred multiple ‘‘is a” inheritances: Multiple par-
ent–child relationships for a term are not present in the asserted
hierarchy. However, a term can have more than one parent in
the inferred hierarchy that is constructed by invoking an appropri-ate ‘‘OWL reasoner” (e.g., Pellet [33]) on the asserted hierarchy.
Rules for inferring these relationships are expressed using OWL
description logics and speciﬁed as OWL necessary and sufﬁcient or
necessary conditions, in the ontology. The OWL reasoner uses the
OWL expressions to create the inferred hierarchy.
4. Sibling disjointedness: Unlike in the BFO, disjoint axioms for
sibling classes are not enforced at all levels in the asserted OWL
hierarchy. The disjointedness is maintained at the upper level of
the ontology formed by the BFO classes. If sibling disjointedness
is applied at a level of the asserted OWL hierarchy, then the follow-
ing principles are considered:
(a) Disjoint axioms are applied only between primitive sibling
classes.
(b) Disjoint axioms are applied to primitive sibling classes only
after thehierarchical level containing theclasses is exhausted,
such that any class added later will not have instances that
overlap with the instances of existing sibling classes.
5. Preferred name and textual deﬁnition: Every OWL class and
OWL property (object, datatype) must have a preferred name and
a textual deﬁnition using the NPO’s OWL annotation properties:
‘‘preferred name” and ‘‘deﬁnition”.
6. Synonym: If a class or OWL property has multiple names,
these names must be provided as synonyms using the NPO’s ‘‘syn-
onym” OWL annotation property.
7. External class reference: Classes borrowed from external
sources should be given their external reference ID using the
‘‘dBXrefID” annotation property. A termmay have multiple dBXref-
IDs if it has mappings to more than one terminology.
8. Code: Every class must have an identiﬁcation code that starts
with the preﬁx ‘‘NPO_” (e.g., NPO_100).
9. rdf: ID and rdf:Label: Every class speciﬁcally deﬁned in the
NPO must have its NPO code as its rdf:ID. The rdf:ID of every class
borrowed from an external ontology found in the OBO Foundry list,
must be preserved in the NPO. Every class in the NPO must also
have its preferred name as its rdf:Label.
The preceding list is included to demonstrate the clear set of
principles used for the initial development and continued growth
of the NPO. Interested readers should refer to the BFO documenta-
tion [30], the NPO documentation (http://npo.wustl.edu/), as well
as other basic references on ontology development [4]. The initial
set of NPO terms were organized based on these design principles
and then expanded based on literature surveys, data curation, and
our own research. Terms that are found in other relevant ontolo-
gies/CVs like GO [8], ChEBI [9], NCI Thesaurus [24], and MeSH
[26] are re-used while developing the NPO.3. Results and discussion
In this section,wepresent the salient features of theNPOusing its
OWL version ‘2010-01-29’ as available from BioPortal (http://bio-
portal.bioontology.org/). The namespace URI for accessing the NPO
is http://purl.bioontology.org/ontology/npo, and the corresponding
namespace is ‘npo’. The OWLDL expressivity of NPO is SHIQ(D). The
NPO has 1564 OWL classes, 45 OWL object properties for specifying
class-level associations, and 5 OWL annotation properties for anno-
tating the classes and object properties. The NPO covers 10 name-
spaces that uniquely identify all the classes in the NPO, and these
along with the number of classes (given in parenthesis) are: bfo
(1), snap (10), span (6), CHEBI(264), GO(83), FIX(17), REX(8),
UO(104), PATO(54), and npo (1017). In this paper, we indicate the
namesof object properties inboldfaced letters as inobject property,
and the names of classes and annotation properties in italics letters
as in Class Name and annotation property, respectively.
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The ﬁve OWL annotation properties of NPO used for annotating
classes and object properties are preferred name, deﬁnition, syno-
nym, code, and dBXrefID.3.1.1. Preferred name
The property preferred name is used to indicate the preferred
name of a class or a class-level association in the NPO. For example,
the preferred name of class Quantum Dot is ‘‘quantum dot”.Fig. 1. OWL object properties and the number of times they a3.1.2. Deﬁnition
The property deﬁnition is used to indicate the meaning or deﬁni-
tionof a class or a class-level association in theNPO. For example, the
deﬁnition of classQuantumDot is ‘‘A three-dimensional nanoparticle
which is made of material that exhibits quantum effects”.3.1.3. Synonym
The property synonym is used to indicate an alternate name of a
class or a class-level association in the NPO. For example, a syno-
nym of class Quantum Dot is ‘‘QD”.re used for asserting class-level associations in the NPO.
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The property code is used to indicate a unique identiﬁcation
code for every class in the NPO. Every code value begins with the
preﬁx ‘‘NPO_” followed by a number. For example, the code for
class Quantum Dot is ‘NPO_589”. The smallest code value is
NPO_100 of class Cylinder, while the highest code value in the cur-
rent version is ‘‘NPO_1663” of class Agent Role.
3.1.5. dBXrefID
The property dBXrefID is used to indicate the reference ID of a
class from an external CV/ontology/database. For example, a dBXre-
fID of class Polymer is CHEBI:33839.
3.2. OWL object properties (class-level associations) in the NPO
The OWL object properties are used to specify associations be-
tween classes, and these are represented in the NPO as shown in
Fig. 1. Also shown in the ﬁgure, are the number of times each of
these properties are used in the NPO. These properties are de-
scribed in Table 1.
3.3. Types of domain-speciﬁc entities represented in the NPO
In Fig. 2, we present the asserted upper-level hierarchy of NPO
that shows how the top-level domain-speciﬁc classes are classiﬁed
under the BFO classes (indicated with asterisks). Entity is the top-
most class in the NPO, and all instances of Entity (entities) are
broadly classiﬁed into two groups – continuants and occurrents.
A continuant (endurant) has no temporal parts and it endures
through time by maintaining its identity at any time in which it ex-
ists (e.g., nanoparticle, dendrimer, scanning electron microscope,
etc.). On the other hand, an occurrent (perdurant) has temporal
parts and it happens, unfolds, or develops through time [30] (e.g.,
assay, active targeting, endocytosis, angiogenesis inhibition, etc.).
By default, each child class (subclass) in the NPO is related to its
parent class through the is a (inheritance) relation. Among contin-
uant classes, the is a relation is interpreted as follows: If C and C1
are continuant classes, then C is a C1 means that every instance of
C, at any time, is an instance of C1 at the same time [34] (e.g., Nano-
particle is a Nanomaterial, Iron Oxide Nanoparticle is a Nanoparticle,
etc.). Among occurrent classes, the is a relation is interpreted as
follows: If P and P1 are occurrent classes, then P is a P1means that
every instance of P is an instance of P1 [34] (e.g., Amide Linkage is a
Covalent Linkage, Targeting is a Process, etc.). As shown in Fig. 2,
continuants are further classiﬁed as independent continuants and
dependent continuants. For a detailed description of all the BFO
classes, the reader is referred to the BFOmanual [30]. In the follow-
ing subsections, we describe the main types of domain-speciﬁc
entities represented in the NPO, based on the examples shown in
Fig. 2.
3.3.1. Types of entities represented as independent continuants
Entities that are represented as independent continuants, in-
clude the following types:
(1) Material entities/objects that are synthesized, characterized
and distinguished at the nanoscale (1–100 nm) length dimension:
these entities are represented by subclasses of Nanomaterial as
shown in Fig. 3A.
(2) Material entities/objects that are distinguished at the molec-
ular level: These entities are represented by subclasses of Atom,
Element, Isotope, and Molecular Entity as shown in Fig. 3B. Most of
the classes in this category can be obtained from the ChEBI ontol-
ogy. The ChEBI asserted OWL hierarchy has multiple is_a inheri-
tances, which are forbidden in the asserted hierarchy of the NPO
through our adoption of the single inheritance principle from
BFO. Thus, we cannot directly import the ChEBI ontology into theNPO. At the same time, we note that multiple inheritances are
inevitable in the description of chemical entities as it is clearly
magniﬁed in ChEBI. Therefore, when using ChEBI terms in the
NPO, we ensure these terms are included in the NPO according
to NPO design principles stated in Section 2.2. Currently, there
are 264 ChEBI classes in the NPO. More terms from ChEBI will be
added, as we need them to make restrictions for other terms in
the NPO to represent knowledge that is speciﬁc to the cancer nano-
technology domain. However, the ChEBI branch will continue to
grow as more terms from ChEBI are added during the development
of the NPO.
(3) Entities which represent instruments used for the prepara-
tion and characterization of nanomaterials: These entities are rep-
resented by subclasses of Instrument as shown in Fig. 3C.
(4) Entities which describe physical sites in a material entity:
These entities are represented under class Material Site as shown
in Fig. 3D.
(5) Entities which describe surfaces of material entities: These
entities are represented under the class Material Boundary as
shown in Fig. 3E.
(6) Entities which are ﬁat parts of material entities: These enti-
ties include different types of molecular parts (e.g., functional
groups) in molecules; linkages or chemical associations between
chemical components in nanoparticle formulations, samples, etc.
These are represented under the class Fiat Material Part as shown
in Fig. 4A. In many cases, nanoparticles contain molecules with
speciﬁc functional groups, which serve as reactive sites for chemi-
cal conjugation with other molecules. Thus, in the ontology, it be-
comes important to represent the type of functional groups that
are present in a given organic compound/molecule [36]. This is
achieved in the NPO by associating ‘‘organic compound” classes
with ‘‘functional group” classes using parthood relations, such as,
part_of and has_part (see Table 1 for examples). The covalent link-
ages (shown in Fig. 4B) in nanoparticle formulations are part of
functional groups, and are derived from functional groups of mol-
ecules that are covalently linked during the synthesis of nanopar-
ticles. Fig. 4C depicts an example of how an amide linkage
formed between a primary amine and a carboxylic acid is repre-
sented in the NPO using part_of and derives_from relations. This
knowledge is useful to determine ways to link different types of
molecules for functionalizing nanoparticles.3.3.2. Types of entities represented as dependent continuants
Entities that are dependent on the existence of other entities are
considered as dependent continuants, and these include the fol-
lowing types:
(1) Entities which describe the quality inhering in material enti-
ties: these entities are represented under the class Quality as
shown in Fig. 5A.
(2) Entities which describe roles of material entities at the
molecular level in a particular context: These entities are
represented under class Molecular Role as shown in Fig. 5B.
(3) Entities which describe functions and dispositions inhering
in a continuant entity: These entities are represented under
the class Function and Disposition, respectively, as shown in
Fig. 5B.
(4) Entities which describe the units of measurements: These
entities are represented under the class Unit Of Measurement
as shown in Fig. 5C. We re-use classes from the unit ontology
(http://purl.org/obo/owl/UO) to represent many of the units
of measurements in the NPO.
(5) Entities which describe the types of chemical interactions
inhering in linkages, and these are represented under the
class Chemical Interaction, as shown in Fig. 5D.
Table 1
OWL object properties (class-level associations) in the NPO.
No. OWL object
property
Deﬁnition and comments Examples
1. has relation to A general relation, which indicates that a class is related to another class
2. has part A transitive parthood relation in which one entity has itself, or another entity as part,
and the relation is valid for use between continuants or between occurrents but not
between a continuant and an occurrent [34,35]. The has part relation between any two
continuant classes is interpreted as follows: If C and C1 are continuant classes, then C
has part C1 means that every instance of C, at any time, has some (one or more)
instances of C1 as parts at the same time [34]. The has part relation between occurrent
classes is interpreted as follows: If P and P1 are occurrent classes, then P has part P1
means that every instance of P has some instances of P1 as parts [34]
Primary Amine has part Primary Amine Group
Thiol has part Sulfhydryl Group
3. part of A transitive parthood relation in which one entity is part of another entity, and the
relation is valid for use between continuants or between occurrents but not between a
continuant and an occurrent. The part of relation between continuants is time-
dependent while between occurrents it is time-independent [34,35]. The part of
relation between any two continuant classes is interpreted as follows: If C and C1 are
continuant classes, then C part of C1means that every instance of C, at any time, is part
of some (one or more) instances of C1 at the same time [34]. The part of relation
between occurrent classes is interpreted as follows: If P and P1 are occurrent classes,
then P part_of P1 means that every instance of P is part of some instances of P1 [34]
Carboxyl Group part of Carboxylic Acid
Dendrimer Generation Layer part of Dendrimer
Sample Preparation part of Study
4. determines
property
A relation that indicates the property determined by a characterization Size Characterization determines property Size
5. function of A relation that indicates the bearer inhering a function Targeting Function function of Targeting Agent
6. has application A relation that indicates the application or use of an entity Western Blot Analysis has application Detection Of
Proteins
7. has bond with A relation, which indicates that one atom has a covalent bond with another atom in a
polyatomic entity
Organoﬂuorine Compound has part (Carbon Atom
\ has bond with Fluorine Atom)
8. has double bond
with
A relation, which indicates that one atom has a double covalent bond with another
atom in a polyatomic entity
9. has single bond
with
A relation which indicates that one atom has a single covalent bond with another atom
in a polyatomic entity
Chlorambucil has part (Carbon Atom \ has single
bond with Fluorine Atom)
10. has triple bond
with
A relation, which indicates that one atom has a triple covalent bond with another atom
in a polyatomic entity
11. has component
part
A relation that is used between material entities where one is composed of the other. In
the NPO, this relationship is used to describe the composition of nanomaterials
It is interpreted as follows: If C and C1 are continuant classes, then C has component
part C1means that every instance ‘‘c” of C is prepared from some instances of ‘‘c1” of C1
and a signiﬁcant material portion of c1 becomes part of the constituting material of ‘‘c”
when ‘‘c” begins to exist
Gold Nanoparticle has component part Gold
Solid Lipid Nanoparticle has component part Lipid
12. has conjugated
component part
A relation which is used to infer that a particular chemical component of a nanoparticle
formulation is attached or chemically conjugated to some other chemical components
of the same formulation
13. has encapsulated
component part
A relation which is used to infer that a particular chemical component becomes
enclosed – due to non-covalent interactions – in a nanoparticle’s material site that is
fully bounded by the particle’s constituting material
14. has entrapped
component part
A relation which is used to infer that a particular component is trapped – due to non-
covalent interactions – in a nanoparticle’s material site that is partially bounded by the
particle’s constituting material
15. has function A relation that indicates the function inhering in an entity Targeting Agent has function Targeting Function
16. is realized in A relation between a realizable entity and an occurrent Emulsifying Role is realized in Emulsiﬁcation
17. has participant A relation between a continuant and an occurrent, which holds if and only if at every
time an instance of the occurrent is created, it has at least one instance of the
continuant participating in it at the same time. Therefore, if P is an occurrent class and C
a continuant class, then P has participant C means that every instance of P involves
some instances of C as participants [34]
Western Blot Analysis has participant Antibody
Folic Acid Metabolism has participant Folic Acid
18. has output
participant
A relation between a continuant and an occurrent that has other participating
continuants, which holds if and only if at every time t an instance of the occurrent is
created, there is at least one instance of the continuant participating in it at time t1 > t,
and it is formed/derived from the instances of those continuants that participate at time
t
Sample Preparation has output participant
Sample
19. has quality A relation that indicates the quality inhering in an entity. It is a general relation used
between any class and a subclass of Quality
Solid Phase has quality Solid State
Quantum Dot has quality Sphere
20. has role A general relation between an independent continuant and role. It is interpreted as
follows: if C is an independent continuant and C1 a role continuant class, then C has
role C1means that every instance of C ﬁlls some instances of role C1 every time the role
is realized in a particular context [34]
Doxorubicin has role Anticancer Drug Role
Targeting Agent has role Targeting Role
21. has technique A relation that indicates the technique used for accomplishing a purpose Imaging has technique Imaging Technique
22. has unit of
measure
A relation that indicates the unit of a measured quantity Length of Time has unit of measure Time Unit
Transfection Efﬁciency has unit of measure
Percent
23. negatively
regulates
A relation between two occurrents where one negatively regulates the other Tumor Angiogenesis Inhibition negatively
regulates Tumor Angiogenesis
24. is integral part of A parthood relation that holds when C part_of C1 and C1 has part C, where C and C1 are
continuant classes
Gold Atom is integral part of Gold
Carbon Atom is integral part of Carbon
(continued on next page)
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Table 1 (continued)
No. OWL object
property
Deﬁnition and comments Examples
25. participates in A relation between a continuant and an occurrent, which holds if and only if at every
time an instance of the continuant is created, it participates in at least one instance of
the occurrent at the same time. Therefore, if C is a continuant class and P is an occurrent
class, then C participates in P means that every instance of C participates in some
instances of P [34]
Scanning Electron Microscope participates in
Scanning Electron Microscopy
26. property
determined from
A relation, which indicates the type of process that determines a qualitative or
quantitative measure of a property
Pharmacokinetic Property property determined
from Pharmacokinetic Study
27. parameter
determined from
A relation, which indicates the type of process that determines the value of a parameter Elimination Half Life parameter determined from
Pharmacokinetics Study
28. quality of A relation between a quality and its bearer Crystalline State quality of Crystal
29. regulates A relation between two occurrents where one regulates the other Regulation Of DNA–RNA Transcription regulates
DNA-Dependent Transcription
30. stimulus causes
response
A relation that indicates the response caused by a stimulus. In the NPO, subclasses of
Nanoparticle Stimulus and Response To Stimulus are associated using this relation
Stimulus Of Infrared Light stimulus causes
response Nanoparticle Response To Stimulus Of
Infrared Light
31. technique used
for
A relation that indicates the process for which the technique is used Imaging Technique technique used for Imaging
32. unit of A relation that indicates the quantity associated with a unit of measure Time Unit unit of Length Of Time
33. uses instrument A relation that indicates the type of instrument used in a process Scanning Electron Microscopy uses instrument
Scanning Electron Microscope
34. positively
regulates
A relation between two occurrents where one positively regulates the other Positive Regulation Of Mitosis positively regulates
Mitosis
35. has property A relation between an entity and a speciﬁcally dependent continuant Lipid has property Amphiphilic
36. bearer of A relation between an entity and a dependent continuant Covalent Linkage bearer of Covalent Interaction
37. contained in A relation between a material continuant and an immaterial continuant, when the
material continuant is located in but shares no parts in common with the immaterial
continuant at the same time [34]
Tumor Extracellular Fluid contained in Tumor
Extracellular Space
38. contains A reciprocal relation of contained in, where given an immaterial continuant at some
time, there is a material continuant contained in the immaterial continuant at the same
time
Intracellular Space of Tumor Cell contains
Intracellular Fluid In A Tumor Cell
39. derives from A relation between distinct material continuants when one succeeds the other across a
temporal divide in such a way that at least a signiﬁcant portion of the matter of the
earlier continuant is inherited by the later [34]
Disulﬁde Linkage Between Two Thiols derives from
Sulfhydryl Group
40. has
identiﬁcation
type
A relation which indicates the name of the type of identiﬁcation, as well as other
attributes of an entity
Dendrimer End Group has identiﬁcation type
Functional Group
41. has agent A relation which is between a process, a continuant and a time whenever the
continuant is a participant in the process and is at the same time directly causally
responsible for its occurrence [34]
Emulsiﬁcation has agent Emulsiﬁer
42. agent in A relation between a continuant and an occurrent in which the continuant participates
in and causes the occurrence of that occurrent
DNA Crosslinking Agent agent in DNA Crosslinking
43. realizes A relation which is between an occurrent and a realizable entity Emulsiﬁcation realizes Emulsifying Role
44. inheres in A relation between a dependent continuant and an entity Drug Toxicity inheres in Anticancer Drug
45. role of A relation that indicates the bearer inhering a role Dye Role role of Dye
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Entities that are processes or parts of processes are considered
as occurrents, and these include the following types:
(1) Entities which describe functions of molecular entities that
are realized as processes. As shown in Fig. 6A, these entities
are represented under classes like Antineoplastic Activity and
Molecular Function – a top-level GO class, which describes
the activity of a gene product at the molecular level.
(2) Entities which describe processes occurring in integrated
living units such as cells, tissues, organs and organisms. As
shown in Fig. 6B, these entities are represented under the
class Biological Process – another top-level GO class, which
describes a biological process in which gene products
participate.
Since the asserted classiﬁcation of GO terms under Molecular
Function and Biological Process does not adhere to the single is a
inheritance principle, we cannot directly import the Gene Ontology
into the NPO. Therefore, when using GO terms, we ensure these
terms are included in the NPO according to NPO design principles
stated in Section 2.2. Currently in the NPO, there are 83 GO classes,
and their hierarchical structures do not resemble those of GO. More
terms from GO will be added as we need them to make restrictionsfor other terms in the NPO to represent knowledge that is speciﬁc
to the cancer nanotechnology domain. As more terms from GO are
addedduring the development of theNPO, the branches ofMolecular
Function and Biological Processwill continue to expand.
(3) Entities which describe the stimulus for activating the
function of a nanoparticle, and response to the stimulus.
As shown in Fig. 7A, these entities are represented under
classes Stimulus and Nanoparticle Response To Stimulus.
(4) Entities which describe tumor targeting mechanisms; these
entities are represented under the class Tumor Targeting, as
shown in Fig. 7A.
(5) Entities which describe studies, experiments and techniques;
these entities are represented under classes Study and Proce-
dure, as shown in Fig. 7B.
3.4. Inferred hierarchy of the NPO
So far, we have discussed the different parts of the asserted
hierarchy and the class-level relationships of the NPO. The main
feature of the asserted hierarchy is that every class is ‘‘is a” related
to not more than one parent class (single is a inheritance), unlike
that of the inferred hierarchy which contains classes with more
than one parent class (multiple is a inheritance). We elucidate this
Fig. 2. Asserted OWL hierarchy showing the BFO-based upper-level classiﬁcation of domain terms in NPO with selected examples.
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ses of Nanotube. As shown in Fig. 8, the following three classes –
Double-Walled Carbon Nanotube, Multi-Walled Carbon Nanotube,
and Single-Walled Carbon Nanotube, have an additional parent class
Carbon Nanotube, which is inferred based on the criteria that all
nanotubes composed of carbon are also instances of Carbon Nano-
tube. Rules for these criteria are expressed in the following OWL
restrictions:
1. Necessary and sufﬁcient condition for Carbon Nanotube: Carbon
Nanotube is a (Nanotube and has part Carbon).
2. Necessary condition for Double-Walled Carbon Nanotube: Dou-
ble-Walled Carbon Nanotube is a (Double-Walled Nanotube and
has part Carbon).
3. Necessary condition for Multi-Walled Carbon Nanotube: Multi-
Walled Carbon Nanotube is a (Multi-Walled Nanotube and has
part Carbon).
4. Necessary condition for Single-Walled Carbon Nanotube: Single-
Walled Carbon Nanotube is a (Single-Walled Nanotube and has
part Carbon).One could also infer ‘‘is a” relationships among sibling classes
without having to assert them explicitly. For example, the subclas-
ses of Nanoparticle (see Fig. 3A) are sibling classes, which are de-
ﬁned, in the NPO, using necessary and sufﬁcient conditions in
relation to subclasses in other branches of the ontology such as
Molecular Entity, Realizable Entity or Quality. When a reasoner reads
the instructions in these OWL deﬁnitions, the nanoparticle classes
re-arrange based on how its related classes are arranged in other
branches of the ontology. For example, the reasoner infers that
Dextran-Coated Nanoparticle ‘‘is a” subclass of Biopolymer-Coated
Nanoparticle, as depicted in Fig. 9.3.5. Applications of the NPO
The NPO can be applied to solving several problems facing
interdisciplinary research in cancer nanotechnology. Here, we
mention a few applications of the NPO:
(1) One particularly challenging aspect of interdisciplinary re-
search such as nanomedicine is the extreme diversity of venues for
Fig. 3. Asserted OWL hierarchy of a subset of NPO classes. (A) Subclasses of Nanomaterial. (B) Subclasses of Molecular Entity, and other classes representing atoms, elements,
and isotopes. (C) Subclasses of Instrument. (D) Subclasses of Material Site. (E) Subclasses of Material Boundary.
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through numerous collections of medical, chemical, physical and
engineering journals. When scientists search for related articles,
they are faced with the problem of searching unfamiliar journals,
and this problem is compounded by variation in terminology be-
tween disciplines. This is particularly true for the ﬁeld of nanomed-
icine where a typical research project might require information
about the chemical synthesis, physicochemical characterization,
in vitro behavior, and in vivo testing of a nanomaterial. Ontologies
such as the NPO can be used to solve this problem by providing (a)
a common set of terminology to help standardize nomenclaturefor indexing and expand searches to include synonymous terms or
topics and (b) semantic search capability: the ability to further ex-
pand or narrow searches based on inheritance relationships and
associations provided by the ontology. Using such capabilities, users
can include related terms in their search without the need for de-
tailed knowledge of the terminology particular to a speciﬁc area of
cancer nanotechnology research. Such semantic search capability
can signiﬁcantly reduce barriers to searching data across disciplines,
and this is very much needed in cancer nanotechnology research.
(2) Another important application of the NPO will be in data
annotation, which can help indexing, integrating and retrieving
Fig. 4. (A) Asserted OWL hierarchy of a subset of classes underMaterial Fiat Part. (B) Asserted OWL hierarchy of subclasses of Linkage. (C) An example showing how an amide
linkage formed between a primary amine and a carboxylic acid are associated to the respective functional groups in the NPO.
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and knowledge discovery. In the past, annotation of data using
ontologies has led to several discoveries through the use of logical
relationships provided by the structure of the ontology; e.g., GO
[37–39]. By providing the necessary deﬁnitions and relationships,
the NPO will facilitate semantic interoperability among different
applications and resources developed to store, search and analyze
research data. Because NPO contains terms from GO and ChEBI it
can provide a unifying knowledge framework to associate nano-
particle data with external data annotated using GO and ChEBI
terms. Thus, applications using the NPO can also draw inferences
from the wide range of annotated data associated with GO and
ChEBI, thereby, facilitating data mining and inferencing. Prelimin-
ary steps for such annotation have been undertaken through the
caOBR tool (manuscript in preparation) which uses the NPO to in-
dex several online resources, including caNanoLab, via the Open
Biomedical Resources [40] technology. Initial caOBR results are
currently available through the Bioportal resource.
3.6. Documentation, availability and download of NPO
The latest information and documentation for NPO are made
available through a wiki that can be accessed at http://npo.wustl.e-
du. Public releases of NPO can be accessed, visualized and down-
loaded through BioPortal (http://purl.bioontology.org/ontology/npo) – a web portal developed by the National Center for Biomed-
ical Ontology. The NPO is also uploaded at the Biomed Grid
Terminology (BiomedGT) Ontology Development Wiki (http://
biomedgt.nci.nih.gov/wiki/index.php/Main_Page), which serves as
a tool for collaborative development and maintenance of ontolo-
gies and other terminologies. Being founded upon well-deﬁned de-
sign principles, the current version of the NPO provides a structure
suitable for collaborative development and future growth of the
NPO.
3.7. NPO as a caBIG vocabulary standard
To facilitate the adoption of NPO into caBIG applications, it is
necessary to get the NPO approved as a caBIG vocabulary stan-
dard by the Vocabulary and Common Data Elements (VCDE) work-
space. Initial review by the VCDE in early 2009 indicated that NPO
met more than 70% of the criteria for structure and content but the
NPO needs a better documentation, a clear editorial process and a
clear governance structure. The NPO met most of the structure cri-
teria related to the following areas: concept orientation, non-
semantic term identiﬁers, polyhierarchical organization, explicit-
ness of relations, recognition of redundancy and extensibility.
The NPO, however, did not have rules for ensuring term perma-
nence. NPO met most of the content criteria related to polyhierar-
chy, rejection of ‘‘not elsewhere classiﬁed” (NEC) terms, context
Fig. 5. Asserted OWL hierarchy of a subset of NPO classes. (A) Subclasses of Quality. (B) Subclasses of Role, Function, and Disposition. (C) Subclasses of Unit Of Measurement. (D)
Subclasses of Chemical Interaction.
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ria related to content coverage, and some terms were not sufﬁ-
ciently well deﬁned to distinguish them from other terms. A
detailed account of the VCDE review of NPO can be accessed from
the link http://gforge.nci.nih.gov/frs/?group_id=471. Progress has
been made in terms of improving the documentation of NPO
through the establishment of the NPO wiki (http://npo.wustl.edu).
A working draft for the editorial process can be viewed at the NPO
wiki (http://npo.wustl.edu/index.php/Editorial_Process).
3.8. NPO governance
To date, a community of interest for NPO has been established
through the activities of caBIG Nanotechnology Working Group,
our participation in NCI Nanotechnology Alliance events, collabo-
ration with the caNanoLab development team, collaboration withNCBO, interaction with the BiomedGT Semantic MediaWiki Project,
and discussions with the Nanotechnology Characterization Lab
(NCL). While this current community of interactions and collabora-
tions provides the basis for long-term growth of NPO, it lacks any
formal organizational structure or structured plans for incorpora-
tion of feedback into ontology development and review cycles
(see next paragraph on governance structure). The community
could grow in many ways, some of the natural interactions include
agencies with existing nanotechnology informatics efforts, such
as Environmental Protection Agency (NBI Knowledgebase
http://oregonstate.edu/nbi/pages) and National Science Founda-
tion (InterNano http://www.internano.org/ and NanoHub http://
www.nanohub.org/).
With continued growth, there is the need for careful mainte-
nance of the ontology. To ensure that the best practices are fol-
lowed in the growth and maintenance of the ontology, future
Fig. 6. Asserted OWL hierarchy of a subset of NPO classes. (A) Subclasses of Antineoplastic Activity and Molecular Function. (B) Subclasses of Biological Process.
Fig. 7. Asserted OWL hierarchy of a subset of NPO classes. (A) Subclasses of Stimulus For Nanoparticle Function, Nanoparticle Response To Stimulus, and Tumor Targeting. (B)
Subclasses of Study, Characterization, and Procedure.
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Fig. 8. Single and multiple inheritances of subclasses of Nanotube, as shown in the
asserted and inferred hierarchies, respectively.
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structure. The governance structure should establish well-deﬁned
development and review cycles, enforce ontology design princi-
ples, ensure term permanence, and handle extensions and revi-
sions in a systematic manner. Such a governance structure
requires long-term support for ontology development to minimize
governance turnover and provide a continuous set of ontology
engineers to maintain the vocabulary. Plans are underway to
establish a governance structure for the NPO through interactionsFig. 9. Example showing how an OWL reasoner infers parent–child relationships amon
Nanoparticle based on their asserted associations to and based on the asserted hierarchywith VCDE workspace members, and through the activities of the
caBIG Nanotechnology Working Group.
In the longer term, the NPO development will beneﬁt frommore
systematic harmonization with other ontologies and vocabularies.
Existing ontology development tools such as BiomedGT Semantic
MediaWiki (http://www.biomedgt.org/) and BioPortal can facili-
tate such harmonization. In effect, this harmonization will make
it easier to integrate developing informatics resources throughout
the nanotechnology community, to share terms and relationships
among different disciplines, to facilitate the broader exchange of
nanotechnology-related information between data sources. Har-
monization, however, is a difﬁcult undertaking that requires a suf-
ﬁciently broad community of research groups and organizations to
motivate participants to engage and contribute. Therefore, com-
munity building is an essential factor for driving the harmonization
process.
4. Conclusions
In this paper, we have reported the development, design princi-
ples, and salient features of the NPO. The NPO is implemented in
OWL and uses BFO as the upper-level ontology to formally and sys-
tematically classify the domain terms. The present scope of the
NPO encompasses knowledge underlying the preparation, chemi-
cal composition, physicochemical characterization, in vitro charac-
terization and in vivo characterization of nanomaterials studied in
cancer nanotechnology research. The NPO shares terms from other
ontologies/CVs such as CHEBI, GO, FIX, REX, UO, PATO, and NCI
Thesaurus.
The NPO is being developed to meet the terminological and
informatics needs in cancer nanotechnology research, such as:
facilitating interdisciplinary discourse among diverse researchg Polymer-Coated Nanoparticle, Biopolymer-Coated Nanoparticle, and Dextran-Coated
of Polymer, Biopolymer, and Dextran, respectively.
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resources that store and exchange nanomaterial data, and provid-
ing knowledge support for data annotation in order to facilitate
semantic integration, knowledge-based searching, unambiguous
interpretation, mining and inferencing of data.
In this paper, we have described the different types of entities
and the relations between entities that are relevant to the domain
of cancer nanotechnology. We also showed where the domain-spe-
ciﬁc entities are classiﬁed under the BFO, and how NPO handles the
representation of multiple inheritances using OWL deﬁned classes.
We note that the NPO is far from being complete and is subject to
corrections, as the ﬁeld of nanomedicine and nanotechnology
informatics continues to develop. Presently, we have laid a founda-
tion for future growth of the NPO. In the path forward, we will con-
tinue to evaluate the NPO to assess its suitability for applications in
different user scenarios (e.g., annotation of data, answering speciﬁc
scientiﬁc questions, etc.), and to identify gaps and errors in the
ontology. We also intend to review the dependent continuant
branch as many of the terms in this branch are under-represented.
It is clear that NPO has overlap with other domain ontologies
(especially GO and ChEBI). We anticipate that more terms will be
added from these external domain ontologies as we ﬁnd use for
them in the cancer nanotechnology domain. We intend to focus
most of our efforts on representing knowledge that is not repre-
sented in these or other domain ontologies but that is essential
to the cancer nanotechnology domain and to the types of applica-
tions that are of interest to the NPO user community. For example,
we have represented covalent linkages in the NPO by relating them
to functional groups of organic molecules. This type of representa-
tion enables one to identify the different ways of functionalizing
nanoparticles using organic compounds, based on knowledge
about the covalent linkages that can be derived from any two func-
tional groups.
As the NPO continues to grow, its scope will expand depending
upon the needs of and feedback from the user community. The
NPO has signiﬁcantly impacted development of the caNanoLab ca-
BIG database application by helping to identify and deﬁne impor-
tant terms and relationships to model the description of
nanoparticles. Continued collaboration with the caNanoLab devel-
opers helps ongoing identiﬁcation of the terminological needs of
caNanoLab and lead to expansion of the scope and application of
the NPO. Currently, we are manually collecting and relating terms
based on literary information to develop the NPO. However, in the
long-term development of the NPO, we plan to develop and apply
semi-automated text-mining methods to evaluate and enrich the
NPO.
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